Dr. Matt Thompson, CEO
We are excited to announce that Dr. Matt Thompson has been appointed as the new CEO for Life Seal Vascular. With an extensive background in vascular health and medtech executive leadership, Dr. Thompson is poised to lead the company through the next phase of innovation and clinical development. We look forward to his guidance as we continue to make strides in advancing vascular solutions. Welcome aboard, Dr. Thompson! ​
​
EVAR Therapy Failure
Requires Repeat Intervention.
EVAR is the Standard of Care for Abdominal Aortic Aneurysm (AAA) repair.
However, mid to long term outcomes are concerning
1
~1 in 3
EVAR patients undergoes a reintervention
55%
of secondary interventions due to blood flow in the aneurysm sac from type II endoleaks
2
Patients with Type II endoleaks
do far worse than those that do not.
3
5x
more risk of
aneurysm related mortality
8x
more risk of
Aneurysm rupture
10x
more risk of
sac enlargement
20x
more risk of
reintervention
Life Seal Vascular's CYGNUM
Aneurysm Sac Management Device
TM
Simple to Use.
Deployable in 5 mins
​
No imaging interference
​
Predictable in location and fit
Only a few SKUs to treat multiple anatomies
Cost Efficient.
Widely Applicable.
Compatible with all EVAR devices
Can be deployed in a wide range of patients and different anatomies
Platform technology for applications in abdominal, iliac, venous and thoracic indications
1. Columbo et. al. Ann Surg 2021; 274: 179
2. Fairman et. al. J Vasc. Surg 2018; 67: 1082
3. Seike et. al. Circulation 2022; 145: 1056